Navigation Links
Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
Date:2/1/2011

ROCKVILLE, Md., Feb. 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2010, on Thursday, February 10, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, February 10, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.The teleconference dial-in numbers are as follows:Domestic callers 1-800-591-6942International callers 1-617-614-4909Participant Passcode 43128562The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, February 10, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, February 17, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 66575807.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
2. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
3. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals Reports First Quarter 2009 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
9. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
10. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
11. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 3.75% Convertible Senior Notes due May 1, 2015 ... $1,000 principal amount or approximately $5.72 per share, effective March 3, ... is adjusted in connection with the regular quarterly dividend of ... who own shares of PDL on March 5, 2015, the record ...
(Date:3/4/2015)... The UPMC Center for Health Security today announced the ... in Biosecurity Initiative (ELBI). As part of our commitment ... UPMC has selected 28 US and international emerging leaders ... biological science, medicine, policy, the military, think tanks and ... and support of the Defense Threat Reduction Agency in ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... 2011 Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ... systems, announced today that its work entitled "Evaluation of ... in Healthy Volunteers" will be presented at the Eleventh ... held in San Francisco, California. "The selection ...
... N.J., Oct. 25, 2011 Quest Diagnostics Incorporated (NYSE: ... has begun the process of identifying a successor to Surya ... Board of Directors has formed a search committee, engaged a ... internal candidates. Dr. Mohapatra has agreed to ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... update on operations and disclosed the outcome of a ... by management and AMT,s Board of Directors that enables ... therapy development. The CHMP,s recent opinion, while not approving ...
Cached Biology Technology:Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA) 2Quest Diagnostics Initiates CEO Succession Process 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... light," winners are able to stop, and take off ... reveals that a similar race goes on in our ... "The research provides new insights into how the brain ... with attention deficit and hyperactivity disorder," study co-author Jeffrey ...
... owner than a lost cat, according to two new studies. , In ... lost dogs were found, compared to just 53 percent of lost cats. ... by a call or visit to an animal shelter. More than one ... or identification tag at the time of its disappearance. , "The ...
... M.D., Professor of Medicine and Pharmacology at the University ... studied about 265 twin pairs over the past few ... , "By studying many traits and genes, we have ... , Studying genetic variations in twins provides scientists with ...
Cached Biology News:Racing neurons control whether we stop or go 2Racing neurons control whether we stop or go 3Lost dogs found more often than lost cats, study suggests 2Lost dogs found more often than lost cats, study suggests 3Twin studies reveal genetic components leading to cardiac and kidney disease 2Twin studies reveal genetic components leading to cardiac and kidney disease 3
Topoisomerase I...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Biology Products: